LymphomaArchives
Alternative splicing patterns in genetic subtypes of diffuse large B-cell lymphoma
Lymphoma 7 min.
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of B-cell lymphomas, comprising approximately 30% of all non-Hodgkin lymphoma cases [1]. This aggressive malignancy primarily affects B-lymphocytes, making rapid and effective therapeutic intervention crucial due to its fast growth rate....
Prognostic impact of procarbazine in R-MPV followed by reduced-dose whole-brain radiotherapy and cytarabine for primary central nervous system lymphoma
Lymphoma 1 min.
The R-MPV regimen—comprising rituximab, methotrexate, procarbazine (PCZ), and vincristine—followed by reduced-dose whole-brain radiotherapy and high-dose cytarabine, is an established treatment for primary central nervous system lymphoma (PCNSL). However, PCZ is occasionally omitted due to...
Multiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report.
Lymphoma 1 min.
Mantle-cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma. Bruton tyrosine kinase inhibitors (BTKi) significantly improve the prognosis of MCL, but their long-term use may induce immunosuppression-related complications, including secondary malignancies. First-generation BTKi such as Ibrutinib...
HIV infection complicated with talaromyces marneffei, tuberculosis, hemophagocytic lymphohistiocytosis and non-Hodgkin lymphoma: a complex case report
Lymphoma 4 min.
HIV-infected individuals with advanced disease are prone to severe immunosuppression, a condition commonly referred to as Acquired Immunodeficiency Syndrome (AIDS) [1], particularly a marked reduction in CD4 + T cell counts, which predisposes them to a wide range of opportunistic infections and malignancies...
